Many cancer drugs remain unproven 5 years after accelerated approval, a study finds The Associated PressHalf of cancer drugs given accelerated approval fail in later trials – STAT STATSpeedier drug approvals hit slowdown as FDA faces scrutiny The Associated PressScripps News-ProPublica investigation sparks Michigan cancer drug bill Scripps NewsStudy: Few FDA-approved targeted cancer drugs meet ESMO benefit benchmarks Regulatory Focus